Brain Edema – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Brain Edema – Pipeline Review, H2 2016’, provides an overview of the Brain Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Brain Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Brain Edema

The report reviews pipeline therapeutics for Brain Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Brain Edema therapeutics and enlists all their major and minor projects

The report assesses Brain Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Brain Edema

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Brain Edema

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Brain Edema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

FibroGen Inc

Pharmazz Inc

Remedy Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Brain Edema Overview 6

Therapeutics Development 7

Pipeline Products for Brain Edema - Overview 7

Pipeline Products for Brain Edema - Comparative Analysis 8

Brain Edema - Therapeutics under Development by Companies 9

Brain Edema - Therapeutics under Investigation by Universities/Institutes 10

Brain Edema - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Brain Edema - Products under Development by Companies 13

Brain Edema - Products under Investigation by Universities/Institutes 14

Brain Edema - Companies Involved in Therapeutics Development 15

FibroGen Inc 15

Pharmazz Inc 16

Remedy Pharmaceuticals Inc 17

Brain Edema - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Drug Profiles 26

Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

FG-4497 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

glyburide - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

PMZ-2123 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Block Aquaporin-4 for Brain Edema - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Brain Edema - Dormant Projects 33

Brain Edema - Product Development Milestones 34

Featured News & Press Releases 34

Jun 08, 2016: Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA 34

Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting 34

Apr 06, 2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report 35

Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema 36

Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference 36

Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016 37

Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Number of Products under Development for Brain Edema, H2 2016 7

Number of Products under Development for Brain Edema – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Brain Edema – Pipeline by FibroGen Inc, H2 2016 15

Brain Edema – Pipeline by Pharmazz Inc, H2 2016 16

Brain Edema – Pipeline by Remedy Pharmaceuticals Inc, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Brain Edema – Dormant Projects, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for Brain Edema, H2 2016 7

Number of Products under Development for Brain Edema – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports